Cello Health (#CLL) – “pleased with the overall progress made so far by the group in maintaining revenue streams and with the effectiveness of cost control measures”

Cello Health (#CLL) – initial $6.4m acquisition of scientific consultancy Innovative Science Solutions

Cello Health (#CLL) – “strong start to the year”, “confident of achieving a successful result in 2018”

Cello Group (#CLL) – “good” H1, remains confident of FY result in line with current expectations

Cello Group (#CLL) – “good start to the year”, outlook “pleasing”

Cello (#CLL) fesses up that it owes an extra £2.1m including fines to VAT man

Cello Group – FY2014 trading statement, still a buy - I am 80% up!

Marketing group Cello (CLL) has updated on “strong trading” for the 2014 calendar year and that it “is confident of a strong trading year ahead”. However, having identified value HERE with the shares at 54p, does this remain the case at a current more than 90p?

Cello Group – interims, more to come from this big share tip winner to date?

Healthcare and consumer strategic marketing group, Cello (CLL) has announced results for the first half of the 2014 calendar year and that it “is confident that current full year expectations will be met”. Having identified value HERE at 54p, the following reviews with the shares currently at 93.5p.

Cello Group – a big winner to date for me, but still more to come?

I identified value in the shares of marketing group Cello (CLL) on this website last year at 54p (see HERE). The following reviews with the shares currently at 92p following an update from the company which includes that “trading for the first six months of 2014 will be well ahead of the same period in 2013 and that it expects to at least meet current full year market expectations”.

Cello Group – a cracking share tip, more to come?

Shares in research and marketing services group Cello (CLL) – now at 90p - have performed excellently since I first highlighted on this website the potential value they offered at this time last year – see HERE. However, having recently announced an acquisition which “is expected to be immediately earnings enhancing” and that it “is confident that the group will deliver half year results in excess of the prior year and that full year expectations will be met”, is there more to come here?

Cello Group – shares further ahead as trading ‘ahead of expectations’, still decent value?

Insight and strategic marketing group, Cello (CLL) has updated on 2013 “revenues and headline profit before tax ahead of consensus market expectations” and that it “starts the year with good momentum from the last quarter of 2013, and, although it is only early in the new year, the board is confident of a strong year for the group”.

Cello Group - half-year trading update a further pleasant sound to bulls

AIM-listed research and marketing group Cello (CLL) has expressed confidence “that trading for the first six months will be well ahead of the same period in 2012 and that current full year expectations will be met”. This is as the company’s pharmaceutical and healthcare business has continued to grow and its business focused on consumer-facing clients “has returned to strong revenue growth and a solid recovery of margins, as expected”...

Cello Group - a pleasant sounding AGM trading update

I first wrote on AIM-listed research and marketing company Cello Group (CLL) when the shares traded at 38p in August 2010.